Dyne Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 63.18, 275.59, 750.1, 1267.1 ], "ebit_estimate": [ -529.95, -523.15, -469.22, -64.43, 235.34 ], "ebitda_estimate": [ -535.64, -536.33, -458.68, null, null ], "net_income_estimate": [ -515.77, -513.07, -457.33, -253.6, 244.99 ], "per_share_eps_estimate": [ -3.08, -2.91, -2.37, -1.34, 1.84 ], "eps_nri_estimate": [ -3.08, -2.93, -2.41, -1.34, 2.6 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 3.82, 2.05, 1.35, null, null ], "pretax_income_estimate": [ -520.85, -528.39, -501.88, -84.28, 187.13 ], "operating_cash_flow_per_share_estimate": [ -2.51, -2.02, -1.41, null, null ], "roa_estimate": [ -51.9, -53.2, -42.5, null, null ], "roe_estimate": [ -64.88, -110.78, -55, null, null ], "gross_margin_estimate": [ null, 86, 86, 85.33, 88 ], "operating_cash_flow_estimate": [ -414.24, -333.38, -232.7, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 12.72 ], "long_term_growth_rate_mean": 10.84, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 11.36, "future_eps_nri_estimate_growth": 10.84, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -39.62, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 23.04 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, 3.69, 7.38, 11.08, 15.51 ], "ebit_estimate": [ -129.38, -133.79, -140.27, -131.89, -131.29, -129.47, -128.93 ], "ebitda_estimate": [ -142, -149, -168, null, null, null, null ], "net_income_estimate": [ -125.52, -130.11, -136.7, -127.86, -125.55, -122.2, -121.52 ], "per_share_eps_estimate": [ -0.76, -0.77, -0.79, -0.75, -0.73, -0.72, -0.71 ], "eps_nri_estimate": [ -0.75, -0.77, -0.79, -0.75, -0.73, -0.72, -0.71 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, 5.24, null, null, null ], "pretax_income_estimate": [ -126.68, -131.65, -139.08, -129.8, -129.42, -127.82, -128.06 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 10.84, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 11.36, "future_eps_nri_estimate_growth": 10.84, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -39.62, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 23.04 }